Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyRegional therapyVisceral SurgeryDiseaseBreast CancerColon CancerEsophageal CancerFallopian Tube CarcinomaGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupAdenocarcinoma of the esophagogastric junction (AEG)EpCAM positiveICD10C15.-C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C50.-C56C57.0C78.6MeSHBreast NeoplasmsCarcinoma, Ovarian EpithelialColorectal NeoplasmsEsophageal NeoplasmsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceAntineoplastic therapySubstanceCatumaxomabCisplatinFluorouracilMitomycinNaCl 0.9%SubstanceCatumaxomabCisplatinFluorouracilMitomycinNaCl 0.9%SubstanceCatumaxomabCisplatinFluorouracilMitomycinNaCl 0.9%SubstanceCatumaxomabCisplatinFluorouracilMitomycinNaCl 0.9%No. Substances12 RadiotherapySupportive therapySubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateSubstanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%ParacetamolSodium ThiosulfateNo. Substances235Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseintraoperativTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlBleedingDiarrheaDyspneaElectrolyte DisturbanceEmetogenicity (MASCC/ESMO)FistulasHematotoxicityIncrease AminotransferasesInfectionsLymphopeniaPainPyrexiaThromboembolic Event only studiesPublicationAuthorElias DGhanipour LGötze THeiss MMKuijpers Avan Driel WDiseaseLokalisiertes oder lokal fortgeschrittenes Magen-Ca oder Karzinom des gastroösopagealen Übergangs Typ II/IIINeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2Peritonealkarzinom durch kolorektales Ca oder Pseudomyxoma peritonii, operabel, T1-T4, Stadium I-IVPeritonealkarzinose, sekundärPeritonealkarzinose, sekundär, EpCAM positivPeritonealkarzinose ausgehend vom kolorektalen Karzinom, ECOG 0-2OriginCologne-Merheim Medical Center, University of Witten-Herdecke, Cologne, GermanyDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, AmsterdamInstitut Gustave Roussy, Ville- juif, Service of Biostatistics, and Lyon- Sud Hospital, Lyon-SudPREVENT - FLOT9 trial of the AIO / CAOGI / ACOUppsala University, Uppsala, SwedenProtocols in Revision 6 protocols foundCatumaxomab (10/20/50/150), Peritoneal Carcinomatosis, Secondary (PID3037 V1.0)EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.1)HIPEC - Cisplatin 75, Adenocarcinoma Esophagogastric Junction and Stomach (PID2710 V1.1)HIPEC - Mitomycin 15 / Cisplatin 75, Peritoneal Carcinomatosis, Secondary (PID121 V3.0)HIPEC - Mitomycin 35, Peritoneal Carcinomatosis, Secondary (PID123 V2.0)
